PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.05%
Negative revenue growth while 3088.T stands at 1.48%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-4.70%
Negative gross profit growth while 3088.T is at 4.91%. Joel Greenblatt would examine cost competitiveness or demand decline.
-30.38%
Negative EBIT growth while 3088.T is at 9.10%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-24.93%
Negative operating income growth while 3088.T is at 14.59%. Joel Greenblatt would press for urgent turnaround measures.
-19.88%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-19.88%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-19.88%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
39.62%
10Y revenue/share CAGR 1.25-1.5x 3088.T's 27.85%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
50.86%
5Y revenue/share CAGR above 1.5x 3088.T's 5.40%. David Dodd would look for consistent product or market expansions fueling outperformance.
25.47%
Positive 3Y CAGR while 3088.T is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
43.16%
Below 50% of 3088.T's 125.93%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
22.93%
5Y net income/share CAGR similar to 3088.T's 23.77%. Walter Schloss might see both on parallel mid-term trajectories.
21.41%
3Y net income/share CAGR above 1.5x 3088.T's 2.91%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
173.04%
10Y equity/share CAGR 1.25-1.5x 3088.T's 127.86%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
113.90%
5Y equity/share CAGR above 1.5x 3088.T's 41.52%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
53.95%
3Y equity/share CAGR above 1.5x 3088.T's 14.00%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
122.22%
Below 50% of 3088.T's 600.00%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
128.57%
5Y dividend/share CAGR above 1.5x 3088.T's 55.56%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
77.78%
3Y dividend/share CAGR above 1.5x 3088.T's 16.67%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
49.38%
Our AR growth while 3088.T is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
6.80%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
0.73%
Asset growth well under 50% of 3088.T's 2.35%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
2.86%
BV/share growth above 1.5x 3088.T's 1.53%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-7.13%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
1.19%
SG&A declining or stable vs. 3088.T's 9.57%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.